
    
      This is a open-label, randomized phase 2 multi-center study of the anti-tumor efficacy of
      ALX148 + pembrolizumab + 5FU and platinum and of pembrolizumab + 5FU and platinum alone in
      patients with metastatic or unresectable, recurrent HNSCC who have not yet been treated for
      their advanced disease. The study comprises of an initial safety lead-in followed by a
      randomized portion.
    
  